Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
immunology/inflammation, advancing six clinical IMiD degrader programs and reporting $1.6 billion in cash to fund operations into 2029. KT-621 (STAT6) progress: Phase Ib atopic dermatitis data showed strong STAT6 degradation and meaningful biomarker changes (FeNO reductions ~25–35% in AD and ~55% in the asthma subgroup) with clinical signals comparable or in some measures superior to dupilumab, supporting Phase IIb dosing and an enriched high-FeNO/high-eosinophil asthma trial (readouts expected in 2027). IRF5 dosing and timelines: Dosing has begun in a healthy-volunteer study of the IRF5 degrader with healthy-volunteer data expected in H2 2026 and an initial proof-of-concept likely in lupus, while Kymera reported clean chronic toxicology data and noted upcoming partner program milestones (Sanofi IRAK4, Gilead CDK2). Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better. Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks Kymera Therapeutics
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswire
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 144
- 3/4/26 - Form 4
- KYMR's page on the SEC website